A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
A considerable proportion of obsessive-compulsive disorder (OCD) patients receiving first-line pharmacological therapy, fail to fully respond to treatment and continue to exhibit significant symptoms. In this systematic review, we evaluate the efficacy of memantine, as a glutamate-modulating agent, in moderate to severe OCD. Single and double blinded as well as open-label trials of memantine augmentation in adults with OCD were considered. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores were the primary outcome measure. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords 'obsessive-compulsive disorder OR OCD' AND 'memantine'. The meta-analysis of eight studies involving 125 OCD subjects receiving memantine augmentation exhibited a significant overall mean reduction of 11.73 points in Y-BOCS scores. The categorical analysis of treatment response (a minimum of 35% reduction in Y-BOCS) in four double-blind placebo-controlled studies indicated that OCD patients receiving memantine augmentation were 3.61 times more likely to respond to treatment than those receiving placebo. We found that 20 mg/day memantine augmentation to first-line pharmacological treatment for a period of at least 8 weeks is a safe and effective intervention for moderate to severe OCD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Understanding heterogeneity in meta-analysis: the role of meta-regression
Baker, W. L., Michael White, C., Cappelleri, J. C., Kluger, J., Coleman, C. I., & From the Health Outcomes, P. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02168.x · Cited by 492
Treatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
Coric, V., Taskiran, S., Pittenger, C., Wasylink, S., Mathalon, D. H., Valentine, G., Saksa, J., Wu, Y.-T., Gueorguieva, R., Sanacora, G., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.04.043 · Cited by 314
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder
Wu, K., Hanna, G. L., Rosenberg, D. R., & Arnold, P. D. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.10.007 · Cited by 264
Nuesch, E., Trelle, S., Reichenbach, S., Rutjes, A. W. S., Burgi, E., Scherer, M., Altman, D. G., & Juni, P. (2009) · BMJ · doi:10.1136/bmj.b3244 · Cited by 248
Denys, D., de Geus, F., van Megen, H. J. G. M., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0803 · Cited by 248
Investigating patient exclusion bias in meta-analysis
Tierney, J. F. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh300 · Cited by 221
Arnold, P., Rosenberg, D., Mundo, E., Tharmalingam, S., Kennedy, J., & Richter, M. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1847-1 · Cited by 202
Veale, D., Miles, S., Smallcombe, N., Ghezai, H., Goldacre, B., & Hodsoll, J. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0317-5 · Cited by 162
Cited by
Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder
Grassi, G., Cecchelli, C., Vignozzi, L., & Pacini, S. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s255375 · Cited by 44
Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Bandeira, I. D., Lins-Silva, D. H., Cavenaghi, V. B., Dorea-Bandeira, I., Faria-Guimarães, D., Barouh, J. L., Jesus-Nunes, A. P., Beanes, G., Souza, L. S., Leal, G. C., et al. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000330 · Cited by 39
Soondrum, T., Wang, X., Gao, F., Liu, Q., Fan, J., & Zhu, X. (2022) · Brain Sciences · doi:10.3390/brainsci12050656 · Cited by 36
A closer look to neural pathways and psychopharmacology of obsessive compulsive disorder
Gargano, S. P., Santos, M. G., Taylor, S. M., & Pastis, I. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1282246 · Cited by 18
Metadata
- Authors
- Modarresi, A., Chaibakhsh, S., Koulaeinejad, N., & Koupaei, S. R.
- Venue
- Psychiatry Research
- Publisher
- Elsevier BV
- Published
- 2019-12
- Volume
- 282
- Pages
- 112602
- ISSN
- 0165-1781 (ISSN-L)
- OpenAlex
- W2978903542
- Cited by
- 61
- References
- 14
- FWCI
- 0.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. https://app.cochat.ai/papers/10.1016/j.psychres.2019.112602
- The paper
- Modarresi, A., Chaibakhsh, S., Koulaeinejad, N., & Koupaei, S. R. (2019). A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Research. https://doi.org/10.1016/j.psychres.2019.112602
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.